123 related articles for article (PubMed ID: 33359138)
1. Outcomes of 3 patients with adenosine deaminase deficiency on long-term enzyme replacement therapy.
Gans MD; Bernstein L; Shliozberg J; Gavrilova T; Rubinstein A
Ann Allergy Asthma Immunol; 2021 May; 126(5):593-595. PubMed ID: 33359138
[No Abstract] [Full Text] [Related]
2. Effects of enzyme replacement therapy on immune function in ADA deficiency patient.
Nakazawa Y; Kawai T; Uchiyama T; Goto F; Watanabe N; Maekawa T; Ishiguro A; Okuyama T; Otsu M; Yamada M; Hershfield MS; Ariga T; Onodera M
Clin Immunol; 2015 Dec; 161(2):391-3. PubMed ID: 26122173
[No Abstract] [Full Text] [Related]
3. Management of ADA-Deficient SCID Patient on Adagen During Pregnancy.
Shams M; Kobrynski L
J Clin Immunol; 2019 Nov; 39(8):846-848. PubMed ID: 31620946
[No Abstract] [Full Text] [Related]
4. Morbidity in an adenosine deaminase-deficient patient during 27 years of enzyme replacement therapy.
Grunebaum E; Reid B; Naqvi A; Hershfield MS; Kim VH; Muller MP; Hicks LK; Lee E; Betschel S; Roifman CM
Clin Immunol; 2020 Feb; 211():108321. PubMed ID: 31812707
[TBL] [Abstract][Full Text] [Related]
5. A 24-Year Enzyme Replacement Therapy in an Adenosine-deaminase-Deficient Patient.
Tartibi HM; Hershfield MS; Bahna SL
Pediatrics; 2016 Jan; 137(1):. PubMed ID: 26684479
[TBL] [Abstract][Full Text] [Related]
6. Burkitt's lymphoma in a patient with adenosine deaminase deficiency-severe combined immunodeficiency treated with polyethylene glycol-adenosine deaminase.
Husain M; Grunebaum E; Naqvi A; Atkinson A; Ngan BY; Aiuti A; Roifman CM
J Pediatr; 2007 Jul; 151(1):93-5. PubMed ID: 17586199
[TBL] [Abstract][Full Text] [Related]
7. Severe combined immunodeficiency due to adenosine deaminase deficiency.
Hussain W; Batool A; Ahmed TA; Bashir MM
J Pak Med Assoc; 2012 Mar; 62(3):297-9. PubMed ID: 22764473
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment with cyclosporine and anti-tumour necrosis factor agent for deficiency of adenosine deaminase-2.
Keino D; Kondoh K; Kim Y; Sudo A; Ohyama R; Morimoto M; Nihira H; Izawa K; Iwaki-Egawa S; Mori T; Kinoshita A
Scand J Rheumatol; 2021 May; 50(3):243-245. PubMed ID: 32720851
[No Abstract] [Full Text] [Related]
9. Treatment of Two Boys Suffering From Deficiency of Adenosine Deaminase Type 2 (DADA2) With TNF-Inhibitor Etanercept.
Krutzke S; Horneff G
J Clin Rheumatol; 2021 Dec; 27(8S):S509-S512. PubMed ID: 31651641
[No Abstract] [Full Text] [Related]
10. First Occurrence of Plasmablastic Lymphoma in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Disease Patient and Review of the Literature.
Migliavacca M; Assanelli A; Ponzoni M; Pajno R; Barzaghi F; Giglio F; Ferrua F; Frittoli M; Brigida I; Dionisio F; Nicoletti R; Casiraghi M; Roncarolo MG; Doglioni C; Peccatori J; Ciceri F; Cicalese MP; Aiuti A
Front Immunol; 2018; 9():113. PubMed ID: 29456531
[TBL] [Abstract][Full Text] [Related]
11. Enzyme replacement therapy of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase (PEG-ADA).
Hershfield MS
Immunodeficiency; 1993; 4(1-4):93-7. PubMed ID: 8167743
[No Abstract] [Full Text] [Related]
12. HCT survival in ADA-SCID: what's the buzz?
Chan SK; Shearer WT
Blood; 2012 Oct; 120(17):3392-3. PubMed ID: 23100302
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of adenosine deaminase deficiency with adenosine deaminase combined with polyethylene glycol].
Girault D; Le Deist F; Debré M; Pérignon JL; Herbelin C; Griscelli C; Sciudery D; Hershfield M; Fischer A
Arch Fr Pediatr; 1992 Apr; 49(4):339-43. PubMed ID: 1497422
[TBL] [Abstract][Full Text] [Related]
14. Deficiency of adenosine deaminase 2: a case series revealing clinical manifestations, genotypes and treatment outcomes from Turkey.
Kisla Ekinci RM; Balci S; Hershfield M; Bisgin A; Dogruel D; Altintas DU; Yilmaz M
Rheumatology (Oxford); 2020 Jan; 59(1):254-256. PubMed ID: 31292637
[No Abstract] [Full Text] [Related]
15. A misleading case of deficiency of adenosine deaminase 2 (DADA2): the magnifying glass of the scientific knowledge drives the tailored medicine in real life.
Maccora I; Frongia I; Azzari C; Ricci S; Cimaz R; Simonini G
Clin Exp Rheumatol; 2018; 36(6 Suppl 115):146. PubMed ID: 30148442
[No Abstract] [Full Text] [Related]
16. Metabolite and thymocyte development defects in ADA-SCID mice receiving enzyme replacement therapy.
Moretti FA; Giardino G; Attenborough TCH; Gkazi AS; Margetts BK; la Marca G; Fairbanks L; Crompton T; Gaspar HB
Sci Rep; 2021 Dec; 11(1):23221. PubMed ID: 34853379
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in understanding and managing adenosine deaminase and purine nucleoside phosphorylase deficiencies.
Grunebaum E; Cohen A; Roifman CM
Curr Opin Allergy Clin Immunol; 2013 Dec; 13(6):630-8. PubMed ID: 24113229
[TBL] [Abstract][Full Text] [Related]
18. Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome.
Nikolajeva O; Worth A; Hague R; Martinez-Alier N; Smart J; Adams S; Davies EG; Gaspar HB
J Clin Immunol; 2015 May; 35(4):366-72. PubMed ID: 25875700
[TBL] [Abstract][Full Text] [Related]
19. How We Manage Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA SCID).
Kohn DB; Gaspar HB
J Clin Immunol; 2017 May; 37(4):351-356. PubMed ID: 28194615
[TBL] [Abstract][Full Text] [Related]
20. Warts and DADA2: a Mere Coincidence?
Arts K; Bergerson JRE; Ombrello AK; Similuk M; Oler AJ; Agharahimi A; Mace EM; Hershfield M; Wouters C; De Somer L; Morren MA; Diego RP; Moens L; Freeman AF; Meyts I
J Clin Immunol; 2018 Nov; 38(8):836-843. PubMed ID: 30386947
[No Abstract] [Full Text] [Related]
[Next] [New Search]
